40525-15-3

Upstream product

• 3556-78-3 cannabidiol 
• 108-73-6 3,5-dihydroxyphenol 
• 6393-56-2 pentylmagnesium chloride 
• 308796-10-3 (1-pentyl)zinc(II) bromide 
• 22972-51-6 (1S,4R)-p-mentha-2,8-dien-1-ol 
• 13956-29-1 CBD 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 112639-10-8 4'-bromocannabidiol 

Downstream Products

• 81780-81-6 10-bromocannabidiol diacetate 
• 57361-65-6 10-Hydroxycannabidiol-triacetat 
• 84872-36-6 10-hydroxy-cannabidiol 
• 13956-29-1 CBD 
• 57361-62-3 10-oxocannabidiol diacetate 
• 125519-09-7 10-hydroxycannabidiol diacetate 
• 52025-76-0 cannabielsoin 
• 54490-19-6 C₂₅H₃₄O₅ 

Relevant academic research and scientific papers

CANNABIDIOL-TYPE CANNABINOID COMPOUND

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.

Structural revision of a Wnt/β-catenin modulator and confirmation of cannabielsoin constitution and configuration

In this report, we revise the structure for a previously reported synthetic product proposed to be the 1R,2S-cannabidiol epoxide and reassign it as cannabielsoin using anisotropic NMR and synthetic chemistry methods. These results provide a direct link to

POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Polymers comprising a plurality of cannabinoids, methods of preparation thereof, and methods of use to treat a number of disease conditions are reported. Also provided are polymer coatings, films, fibers, and non-woven fabrics for a variety of topical app

CATALYTIC CANNABINOID PROCESSES AND PRECURSORS

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.

Synthesis of CBD and Its Derivatives Bearing Various C4′-Side Chains with a Late-Stage Diversification Method

A novel synthetic route for making (-)-CBD and its derivatives bearing various C4′-side chains is developed by a late-stage diversification method. Starting from commercially available phloroglucinol, the key intermediate (-)-CBD-2OPiv-OTf is efficiently and regioselectively prepared and further undergoes Negishi cross-coupling to furnish (-)-CBD. This approach allowed an efficient synthesis of (-)-CBD in a five-step total 52% yield on a 10 g scale. Furthermore, diversification on the C4′-side chain with this method can be realized in a wide range.

Cannabimovone, a cannabinoid with a rearranged terpenoid skeleton from hemp

An investigation of the polar fractions from a nonpsychotropic variety of hemp (Cannabis sativa L.) afforded cannabimovone (6), a polar cannabinoid with a rearranged 2(3→4) abeo-terpenoid skeleton, biogenetically originating from the intramolecular aldolization of a 2′,3′-seco-menthanyl precursor. The structure of cannabimovone was elucidated by spectroscopic analysis, whereas attempts to mimic its biogenetic derivation from cannabidiol (2) gave only anhydrocannabimovone (12), the intramolecular oxy-Michael adduct of the crotonized version (11b) of the elusive natural products. Biological evaluation of cannabimovone (6) against metabotropic (CB1, CB 2) and ionotropic (TRPs) cannabinoid receptors showed a significant activity only for ionotropic receptors, especially TRPV1, whereas anhydrocannabimovone (12) exhibited strong activity at both, ionotropic and metabotropic cannabinoid receptors. Overall, the biological profile of anhydrocannabimovone (12) was somewhat similar to that of THC (4), suggesting a remarkable tolerance to constitutional and configurational changes.

PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME

Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.

Halogenation of Phenols and Phenyl Ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid

Several types of phenyl ethers have been monobrominated in the ring in good yields with potassium bromide in the presence of 18-crown-6 on oxidation with m-chloroperbenzoic acid.Monoiodination takes place with both phenyl ethers and free phenols when potassium iodide is employed.